Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Short term Debt: 2010-2024

Historic Short term Debt for Cytokinetics (CYTK) over the last 8 years, with Dec 2024 value amounting to $11.5 million.

  • Cytokinetics' Short term Debt rose 38.24% to $17.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 38.24%. This contributed to the annual value of $11.5 million for FY2024, which is 14.29% up from last year.
  • Latest data reveals that Cytokinetics reported Short term Debt of $11.5 million as of FY2024, which was up 14.29% from $10.1 million recorded in FY2023.
  • In the past 5 years, Cytokinetics' Short term Debt ranged from a high of $11.5 million in FY2024 and a low of $958,000 during FY2022.
  • Moreover, its 3-year median value for Short term Debt was $10.1 million (2023), whereas its average is $7.5 million.
  • Data for Cytokinetics' Short term Debt shows a peak YoY skyrocketed of 952.19% (in 2023) over the last 5 years.
  • Cytokinetics' Short term Debt (Yearly) stood at $958,000 in 2022, then spiked by 952.19% to $10.1 million in 2023, then grew by 14.29% to $11.5 million in 2024.